Account
Orders
Advanced search
Louise Reader
Read on Louise Reader App.
This book reviews recent advances in drug discovery for Alzheimer’s disease, focusing on major targets and approaches. Topics include approaches to targeting—directly or indirectly—the two proteins that pathologically accumulate in the brain in Alzheimer’s disease, the amyloid β-peptide and the microtubule-associated protein tau, which remain top targets for disease prevention and treatment. A chapter on the emerging area of AI approaches to drug repurposing and discovery will also be included, with examples of the use of big data to identify novel therapeutic modalities. An overview chapter will put these approaches into broader context; describe other important and emerging approaches, targets, and drug candidates; and provide a critical assessment of the potential of these approaches to lead to effective therapeutics. This book is particularly appealing to researchers, clinicians, and students in the fields of medicinal chemistry, neuroscience, pharmacology, and biomedical sciences, as well as anyone interested in the latest advancements in Alzheimer’s disease research and drug discovery.
Les livres numériques peuvent être téléchargés depuis l'ebookstore Numilog ou directement depuis une tablette ou smartphone.
PDF : format reprenant la maquette originale du livre ; lecture recommandée sur ordinateur et tablette EPUB : format de texte repositionnable ; lecture sur tous supports (ordinateur, tablette, smartphone, liseuse)
DRM Adobe LCP
LCP DRM Adobe
This ebook is DRM protected.
LCP system provides a simplified access to ebooks: an activation key associated with your customer account allows you to open them immediately.
ebooks downloaded with LCP system can be read on:
Adobe DRM associates a file with a personal account (Adobe ID). Once your reading device is activated with your Adobe ID, your ebook can be opened with any compatible reading application.
ebooks downloaded with Adobe DRM can be read on:
mobile-and-tablet To check the compatibility with your devices,see help page
Michael Wolfe is the Mathias P. Mertes Professor of Medicinal Chemistry at the University of Kansas, USA, where he has worked since 2016. He began his academic career at the University of Tennessee in Memphis in 1994, before moving to Harvard Medical School and Brigham and Women’s Hospital in 1999. He was appointed Professor of Neurology in 2008. His research career has been dedicated elucidating the molecular basis of Alzheimer’s and related disorders and identifying effective pharmacological interventions. Awards for his work include the MetLife Award for Biomedical Research (2008), a Zenith Fellows Award from the Alzheimer’s Association (2008), and the Potamkin Prize from the American Academy of Neurology (2009).
Sign up to get our latest ebook recommendations and special offers